Vanda plans supplemental NDA filing for Hetlioz after Phase III win
Vanda said Phase III met its primary endpoint in delayed sleep-wake phase disorder, shifting sleep onset 37.1 minutes earlier than placebo (p=0.022), and plans to meet FDA and file an sNDA seeking a new indication.